title: Stimuli that induce a cholinergic neuronal phenotype of NG108-15 cells upregulate ChAT and VAChT mRNAs but fail to increase VAChT protein.
abstract: The vesicular acetylcholine transporter (VAChT) and choline acetyltransferase (ChAT) are encoded by genes organized in a single gene locus, and coregulation of the transcription of the two genes has been repeatedly reported in cholinergic tissues. In the present study, different stimuli were used to induce the differentiation of the hybridoma cells NG108-15 and we examined their effects on the modulation of VAChT and ChAT expression at the mRNA and protein levels. All agents upregulated the VAChT and ChAT mRNA levels, but to a different extent. ChAT activity was increased by retinoic acid, dexamethasone, and dibutyrylcyclic AMP (dbcAMP), and a synergistic effect was observed with a combined dexamethasone and dbcAMP treatment. Nonetheless, no changes in the VAChT protein level could be observed, as judged from ligand binding studies as well as from immunochemical detection. Hemicholinium-3-sensitive choline uptake, hemicholinium-3 binding, and acetylcholine content were increased by differentiating agents, with a rank order of potency comparable to their effects on ChAT activity. Prominent changes were observed in the expression of vesicular protein markers, particularly with the associated treatment dexamethasone and dbcAMP. Thus, it appears that although the different stimuli we have been using are able to stimulate neuronal features and activate the transcription of cholinergic genes, they did not contrive to increase the level of VAChT protein in these cells.
authors: Institute of Physiology, CAS, Prague, Czech Republic.
authors: V
authors: V
authors: Dolezal
authors: X
authors: X
authors: Castell
authors: M
authors: M
authors: Tomasi
authors: M F
authors: MF
authors: Diebler
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism*; D002460:Cell Line; D002794:Choline / Q000378:metabolism; D002795:Choline O-Acetyltransferase / Q000187:drug effects / Q000378:metabolism*; D003907:Dexamethasone / Q000494:pharmacology; D006825:Hybridomas / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007641:Keratolytic Agents / Q000494:pharmacology; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000378:metabolism; D010641:Phenotype; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism*; D014158:Transcription, Genetic / Q000187:drug effects / Q000502:physiology*; D014212:Tretinoin / Q000494:pharmacology; D050494:Vesicular Acetylcholine Transport Proteins; D033921:Vesicular Transport Proteins
chemical_list: D000893:Anti-Inflammatory Agents; D002352:Carrier Proteins; D007641:Keratolytic Agents; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D050494:Vesicular Acetylcholine Transport Proteins; D033921:Vesicular Transport Proteins; D014212:Tretinoin; D003994:Bucladesine; D003907:Dexamethasone; D002795:Choline O-Acetyltransferase; D002794:Choline; D000109:Acetylcholine